GlobeNewswire·Nov 11, 2026, 7:30 AM ET

MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies

INKT

MiNK Therapeutics reported its first pre-commercial product revenue of $0.2 million from agenT-797 supplied via physician-requested named-patient access in multiple countries outside the U.S.
The company was selected by ARPA-H's BoSS program as the cell therapy for a Draper-led team to develop living medicines deployable at room temperature, with up to $87 million in program-wide funding.
A randomized Phase 2 ARDS trial (C-1300-02) is enrolling in Lviv, Ukraine, with U.S. dosing expected before year-end to treat patients facing ~40% 28-day mortality.
Data presented at SITC 2026 showed agenT-797 & MiNK-215 act as "living senolytics" to clear chemotherapy-induced senescent cells, while agenT-797 unlocked tumor-cell killing in MSS colorectal cancer organoids.
Financial results showed a 23% year-over-year improvement in net loss per share ($0.50 vs $0.65) & a 44% reduction in general & administrative expenses to $1.0 million.
Cash & cash equivalents ended the quarter at $7.5 million, with cash used in operations decreasing to $1.3 million, marking the most capital-efficient quarter of 2026.
Two externally funded clinical programs advanced: an investigator-sponsored Phase 2 study at Scripps for MSS colorectal cancer & a Phase 1 study at the University of Wisconsin for GvHD prevention expected to dose by December 2026.
Upcoming milestones include activating U.S. ICU sites before year-end, meeting with the FDA on adaptive trial design, & reporting randomized ARDS trial data in the second half of 2027.

Company: MiNK Therapeutics
Keywords: Nasdaq:INKT, MiNK Therapeutics, INKT, cell therapy, ARDS, Gastroesophageal, agenT797, SITC